Researchers recently published the findings of the ADVANCE SC trial regarding Subcutaneous Efgartigimod PH20. This Phase 3, multicenter study evaluated the safety and efficacy of the drug in adults with primary immune thrombocytopenia (ITP). Primary ITP features an autoimmune destruction of platelets, which results in low counts and significant bleeding risks. Consequently, medical professionals continuously seek new therapeutic options to improve patient quality of life. Additionally, they aim to reduce treatment burdens for those suffering from chronic conditions. The study aimed to determine if the subcutaneous formulation could replicate the clinical success seen with the previous intravenous version.

Clinical Findings for Subcutaneous Efgartigimod PH20

The ADVANCE SC trial focused on a heavily pre-treated population of patients with chronic or persistent ITP. Specifically, participants received either the study drug or a placebo over a 24-week period. Moreover, many participants had received at least three prior lines of therapy before their enrollment. However, the trial did not meet its primary efficacy endpoint of sustained platelet count response in the chronic ITP group. Notably, only 13.7% of treated patients achieved the response compared to 16.2% in the placebo arm. Therefore, the difference between the two groups was not statistically significant for this specific population.

Safety and Future Considerations

Despite the efficacy results, researchers noted that patients tolerated Subcutaneous Efgartigimod PH20 well throughout the duration of the study. Specifically, the safety profile remained consistent with previous trials of neonatal Fc receptor (FcRn) antagonists. Furthermore, the subcutaneous administration provides a more convenient option than traditional intravenous infusions. In addition, most adverse events were mild or moderate, involving common injection site reactions. Consequently, investigators are conducting additional analyses to better understand the variability in patient responses. As a result, clinicians await the full dataset to guide future treatment strategies for refractory ITP.

Frequently Asked Questions

What was the primary goal of the ADVANCE SC trial?

The study aimed to evaluate the efficacy and safety of subcutaneous efgartigimod PH20 specifically for achieving sustained platelet responses in adults with primary ITP.

How does the drug work in ITP management?

The medication acts as an FcRn antagonist. Therefore, it blocks the recycling of IgG antibodies, leading to a rapid reduction in the autoantibodies that destroy platelets.

Was the primary endpoint met in the chronic ITP population?

No, the trial did not demonstrate a statistically significant difference in sustained platelet response between the treatment and placebo groups for the chronic ITP cohort.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. The information provided should not be used to diagnose or treat any health problem or disease. Patients should always seek the advice of their physician or another qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Cooper N et al. Efficacy and Safety of Subcutaneous Efgartigimod PH20 in Adults With Primary Immune Thrombocytopenia (ADVANCE SC): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled, Phase 3 Trial. Am J Hematol. 2026 Apr 06. doi: 10.1002/ajh.70303. PMID: 41943179.

Broome CM et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;402(10411):1405-1416.

Newland AC et al. Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia. Am J Hematol. 2020;95(2):178-187.